NOVARTIS (CQAW039A2317)

By June 19, 2019 Ongoing/In Follow Up

A 12-week, multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma

Leave a Reply